Prevalence and predictors for lipodystrophy syndrome among HIV infected children on anti-retroviral therapy

Authors

  • Anirban Mandal Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
  • Amitabh Singh Chacha Nehru Bal Chikitsalaya, New Delhi

DOI:

https://doi.org/10.18203/2349-3291.ijcp20162413

Keywords:

Lipodystrophy syndrome, Anti-retroviral therapy

Abstract

First of all, the efforts made by the authors in trying to find out the prevalence and more importantly the predictors of lipodystrophy syndrome in HIV infected children on anti-retroviral therapy is much appreciated.1 But, the study was undertaken with the patients mostly (72%) on stavudine based therapy which is not currently being used as first line therapy in adolescents and adults due to many long-term toxicities including lipodystrophy.2 The strong association is also very evident in the present article and makes the finds of high prevalence of these metabolic abnormalities predictable. Clinical method applied for assessing “fat redistribution” encompassed both ‘lipo-atrophy’ and ‘lipo-hypertrophy’. Therefore, the high prevalence of fat redistribution (39.8%) may be due to the wasting present in these children secondary to their malnutrition which would contribute to ‘lipo-atrophy’ and thus fat redistribution.

Metrics

Metrics Loading ...

References

Sanjeeva GN, Pavithra HB, Sukanya V, Shobha S. Prevalence and predictors for lipodystrophy syndrome among HIV infected children on anti-retroviral therapy. Int J Contemp Pediatr. 2016;3:41-51.

National AIDS Control Organisation. Pediatric antiretroviral therapy (ART) guidelines. 2013. http://www.naco.gov.in/upload/2014%20mslns/CST/Pediatric_14-03-2014.pdf. Accessed on 14 February 2016.

Mandal A, Mukherjee A, Lakshmy R, Kabra SK. Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy. Indian J Pediatr. 2015 Sep 3.

Musiime V, Cook A, Kayiwa J, Zangata D. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV infected children in the CHAPAS-3-Trial.Antiviral Therapy. 2013;10: 3851/IMP2695.

Desai N, Mullen P, Mathur M. Lipodystrophy in pediatric HIV. Indian J of Pediatr. 2008;75:351-4.

Aurpibul L, Puthanakit T, Lee B, Mangklabruks A. Lipodystrophy and metabolic changes in HIV infected children on non-nucleoside reverse transcriptase inhibitor based antiretroviral therapy. Antivir Ther. 2007;12:1247-54.

Kanjanavanit S, Puthanakit T, Vibol U, Kosalaraksa P, Hansudewechakul R, Ngampiyasakul C, et al. High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression. Antivir Ther. 2011;16:1351-5.

Downloads

Published

2016-12-21

How to Cite

Mandal, A., & Singh, A. (2016). Prevalence and predictors for lipodystrophy syndrome among HIV infected children on anti-retroviral therapy. International Journal of Contemporary Pediatrics, 3(3), 1142–1142. https://doi.org/10.18203/2349-3291.ijcp20162413

Issue

Section

Letter to the Editor